Cancer Research SABCS  Jordan
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by French, C. A.
Right arrow Articles by Fletcher, J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by French, C. A.
Right arrow Articles by Fletcher, J. A.
[Cancer Research 63, 304-307, January 15, 2003]
© 2003 American Association for Cancer Research


Advances in Brief

BRD4-NUT Fusion Oncogene

A Novel Mechanism in Aggressive Carcinoma1

Christopher A. French2, Isao Miyoshi, Ichiro Kubonishi, Holcombe E. Grier, Antonio R. Perez-Atayde and Jonathan A. Fletcher

Department of Pathology, Brigham and Women’s Hospital, Boston, Massachusetts 02115 [C. A. F., J. A. F.]; Departments of Pathology [A. R. P-A.], and Medicine [H. E. G., J. A. F.], Children’s Hospital, Boston, Massachusetts 02115; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115 [H. E. G., J. A. F.]; and Kochi Medical School, Okohcho, Nankoku, Kochi, Japan 783-8505 [I. M., I. K.]

The poorly differentiated carcinoma with t(15;19)(q13, p13.1) is characterized by its highly aggressive, invariably lethal clinical course. The chromosome 19 translocation breakpoint targets the BRD4 double bromodomain-containing gene, which functions in regulation of cell cycle progression. Herein we demonstrate that BRD4 is fused with nearly the entire transcript of the novel 15q13 gene, NUT (nuclear protein in testis), forming a 6.4-kb fusion oncogene, BRD4-NUT. NUT, like BRD4, is predicted to encode a nuclear protein but, unlike the ubiquitous BRD4 transcript, is expressed only in testis. These findings establish a model to elucidate the oncogenic consequences of unscheduled NUT expression and altered BRD4 function. Very few fusion oncogenes have been identified in epithelial tumors, and BRD4-NUT is the first fusion oncogene mechanism identified in a highly lethal form of carcinoma.




This article has been cited by other articles:


Home page
Cancer Res.Home page
J. L. Ordonez, D. Osuna, D. Herrero, E. de Alava, and J. Madoz-Gurpide
Advances in Ewing's Sarcoma Research: Where Are We Now and What Lies Ahead?
Cancer Res., September 15, 2009; 69(18): 7140 - 7150.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
G. Zheng, M.-R. Schweiger, G. Martinez-Noel, L. Zheng, J. A. Smith, J. W. Harper, and P. M. Howley
Brd4 Regulation of Papillomavirus Protein E2 Stability
J. Virol., September 1, 2009; 83(17): 8683 - 8692.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S.-Y. Wu and C.-M. Chiang
The Double Bromodomain-containing Chromatin Adaptor Brd4 and Transcriptional Regulation
J. Biol. Chem., May 4, 2007; 282(18): 13141 - 13145.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. E. Lenburg, A. Sinha, D. V. Faller, and G. V. Denis
Tumor-specific and Proliferation-specific Gene Expression Typifies Murine Transgenic B Cell Lymphomagenesis
J. Biol. Chem., February 16, 2007; 282(7): 4803 - 4811.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
M. Ottinger, T. Christalla, K. Nathan, M. M. Brinkmann, A. Viejo-Borbolla, and T. F. Schulz
Kaposi's Sarcoma-Associated Herpesvirus LANA-1 Interacts with the Short Variant of BRD4 and Releases Cells from a BRD4- and BRD2/RING3-Induced G1 Cell Cycle Arrest
J. Virol., November 1, 2006; 80(21): 10772 - 10786.
[Abstract] [Full Text] [PDF]


Home page
Genes Dev.Home page
S.-Y. Wu, A-Y. Lee, S. Y. Hou, J. K. Kemper, H. Erdjument-Bromage, P. Tempst, and C.-M. Chiang
Brd4 links chromatin targeting to HPV transcriptional silencing
Genes & Dev., September 1, 2006; 20(17): 2383 - 2396.
[Abstract] [Full Text] [PDF]


Home page
J. Med. Genet.Home page
N Haruki, K S Kawaguchi, S Eichenberger, P P Massion, A Gonzalez, A F Gazdar, J D Minna, D P Carbone, and T P Dang
Cloned fusion product from a rare t(15;19)(q13.2;p13.1) inhibit S phase in vitro
J. Med. Genet., July 1, 2005; 42(7): 558 - 564.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
C. A. French, J. L. Kutok, W. C. Faquin, J. A. Toretsky, C. R. Antonescu, C. A. Griffin, V. Nose, S. O. Vargas, M. Moschovi, F. Tzortzatou-Stathopoulou, et al.
Midline Carcinoma of Children and Young Adults With NUT Rearrangement
J. Clin. Oncol., October 15, 2004; 22(20): 4135 - 4139.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
R. J. Greenwald, J. R. Tumang, A. Sinha, N. Currier, R. D. Cardiff, T. L. Rothstein, D. V. Faller, and G. V. Denis
E{micro}-BRD2 transgenic mice develop B-cell lymphoma and leukemia
Blood, February 15, 2004; 103(4): 1475 - 1484.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
C. Pivot-Pajot, C. Caron, J. Govin, A. Vion, S. Rousseaux, and S. Khochbin
Acetylation-Dependent Chromatin Reorganization by BRDT, a Testis-Specific Bromodomain-Containing Protein
Mol. Cell. Biol., August 1, 2003; 23(15): 5354 - 5365.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2003 by the American Association for Cancer Research.